Event Profile

Go Back

The percentage of issued Biotechnology patents that have been petitioned for IPR is higher than when compared to other technology areas. And yet, Biotech IPRs have the lowest percentage of institution rates. In this webinar, the speakers will discuss what might be behind these numbers and what they mean for petitioners and responders in the biotech field. Key cases and their relevance to IPR practice and prosecution will be presented. Whether or not IPRs are going to survive as a procedure for patent invalidation remains to be decided by the Supreme Court, which will review their constitutionality in the case of Oil States Energy Services, LLC v. Greene’s Energy Group, LLC. Meanwhile, there is a lot to learn from what has happened already.

P...